帕唑帕尼(GW786034)联合环磷酰胺治疗铂耐药复发经治卵巢癌患者——PACOVAR试验结果
多中心I期试验评估帕唑帕尼联合节拍式口服环磷酰胺治疗铂耐药复发经治卵巢癌、腹膜癌或输卵管癌的最佳剂量、活性与耐受性;16例患者中位年龄66岁,最大耐受剂量为帕唑帕尼每日600mg,中位无进展生存期8.35个月、总生存期24.95个月。
要点
- 帕唑帕尼每日600mg联合环磷酰胺每日50mg为最大耐受剂量。
- 中位无进展生存期8.35个月,中位总生存期24.95个月。
- 4例患者发生5例次严重不良事件。
核心结论
- 帕唑帕尼每日600mg口服联合节拍式环磷酰胺每日50mg口服是铂耐药复发上皮性卵巢癌患者的可行方案,在该经治人群中显示出有前景的活性。
研究设计与样本
- 多中心I期试验,评估帕唑帕尼联合节拍式环磷酰胺治疗铂耐药复发经治卵巢癌、腹膜癌或输卵管癌的最佳剂量、活性与耐受性。
- 共16例患者接受治疗,平均年龄66岁。
- 环磷酰胺50mg联合帕唑帕尼每日400至800mg。
主要发现
- 剂量水平I和II中,6例患者中1例出现剂量限制性毒性(DLT)。
- 剂量水平III中,4例患者中2例出现DLT,导致最大耐受剂量(MTD)为帕唑帕尼每日600mg。
- 中位给药周期数为6(范围2-13),其中3例患者治疗至少13个月。
- 中位无进展生存期(PFS)为8.35个月,中位总生存期(OS)为24.95个月。
- 发生155例不良事件(AE),最常见为肝酶升高、白细胞减少、腹泻和乏力;4例患者共发生5例严重不良事件(SAE)。
关键数值与推荐
- 最大耐受剂量(MTD)为帕唑帕尼每日600mg口服联合环磷酰胺每日50mg口服。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The prognosis is poor for patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC). Evidence suggests that antiangiogenic treatment modalities could play a major role in EOC. A combined therapy consisting of the investigational oral antiangiogenic agent pazopanib and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with recurrent, previously treated EOC. PATIENTS AND METHODS: This study was designed as a multicenter phase I trial evaluating the optimal dose as well as activity and tolerability of pazopanib with metronomic cyclophosphamide in the treatment of patients with recurrent, platinum-resistant, previously treated ovarian, peritoneal, or fallopian tube cancer. Here, 50mg cyclophosphamide were combined with 400 to 800mg pazopanib daily. RESULTS: Sixteen patients were treated; mean age was 66years. At dose levels (DL) I and II, one instance of dose-limiting toxicity (DLT) was seen in one of 6 patients. At DL III, two of four patients showed a DLT, leading to a maximum tolerated dose (MTD) of 600mg pazopanib daily. Median number of administered cycles was 6 (2-13), with three patients being treated for at least 13months. Median progression-free survival (PFS) and overall survival (OS) were 8.35months and 24.95months, respectively. 155 adverse events (AE) occurred, most frequently elevation of liver enzymes, leukopenia, diarrhea and fatigue. Altogether, five serious adverse events (SAE) developed in four patients. CONCLUSION: Pazopanib 600mg daily p.o. and metronomic cyclophosphamide 50mg daily p.o. is a feasible regimen for patients with recurrent platinum-resistant EOC and showed promising activity in this previously treated patient population. TRIAL REGISTRATION: Clin.trial.gov registry no.: NCT01238770.
引用
- Dinkic C, Eichbaum M, Schmidt M, et al. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. Gynecol Oncol. 2017. PMID: 28528917. doi:10.1016/j.ygyno.2017.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。